Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A Review
Introduction and purpose: Insufficient efficacy and adverse effects of classical therapies for inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn's disease, have prompted the search for new, more targeted treatment methods. Janus kinase (JAK) inhibitors are a new group of or...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2025-05-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/60398 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849311657426157568 |
|---|---|
| author | Olimpia Wiciun Karolina Skonieczna Kacper Ordon Magdalena Badziąg Paulina Szulc Laura Kurczoba Martyna Kłossowska Olga Kądziołka |
| author_facet | Olimpia Wiciun Karolina Skonieczna Kacper Ordon Magdalena Badziąg Paulina Szulc Laura Kurczoba Martyna Kłossowska Olga Kądziołka |
| author_sort | Olimpia Wiciun |
| collection | DOAJ |
| description | Introduction and purpose: Insufficient efficacy and adverse effects of classical therapies for inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn's disease, have prompted the search for new, more targeted treatment methods. Janus kinase (JAK) inhibitors are a new group of oral drugs that modulate the proinflammatory cytokine signaling pathway. The aim of this review is to present the state of knowledge on the efficacy and safety of currently registered JAK inhibitors in the treatment of IBD.
Review Methods: A systematic search of the PubMed database was conducted, focusing on publications from the last five years as well as selected key earlier studies. The search strategy included relevant keywords related to Janus kinase (JAK) inhibitors and inflammatory bowel disease (IBD). The most pertinent articles aligned with the study objective were reviewed and included.
State of knowledge: JAK inhibitors, such as tofacitinib, upadacitinib, and filgotinib, have shown high efficacy in the treatment of moderate to severe UC and CD, especially in patients with insufficient biological therapy response. Clinical studies confirm their efficacy in inducing and maintaining remission and improving endoscopic findings. The most common adverse events are infections (including herpes zoster), and elevation of creatine kinase and lipids. The safety profile remains acceptable, although it requires monitoring, especially at higher doses, and further investigation.
Summary: JAK inhibitors are an effective and promising therapeutic option for IBD, offering a rapid onset of action and good symptom control. Despite the favorable clinical effects, an individual approach to treatment and monitoring for adverse effects are necessary, especially with long-term use.
|
| format | Article |
| id | doaj-art-ef7ae8c5855c4c9891b4ffb979ffc5d0 |
| institution | Kabale University |
| issn | 2450-3118 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-ef7ae8c5855c4c9891b4ffb979ffc5d02025-08-20T03:53:18ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182025-05-014110.12775/QS.2025.41.60398Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A ReviewOlimpia Wiciun0https://orcid.org/0009-0005-0318-5527Karolina Skonieczna1https://orcid.org/0009-0009-0153-7444Kacper Ordon2https://orcid.org/0009-0000-1764-3422Magdalena Badziąg3https://orcid.org/0009-0008-8598-1034Paulina Szulc4https://orcid.org/0009-0007-7614-9214Laura Kurczoba5https://orcid.org/0009-0004-1330-991XMartyna Kłossowska6https://orcid.org/0009-0002-7444-1637Olga Kądziołka7https://orcid.org/0009-0006-1052-4504Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland, Jagiellońska 13/15, 85-067 BydgoszczCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland, Jagiellońska 13/15, 85-067 BydgoszczCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland, Jagiellońska 13/15, 85-067 BydgoszczUniversity Clinical Center in Gdansk, Poland 80-952 Gdansk, Debinki 7Dr Jan Biziel's University Hospital No. 2 Ujejskiego 75, 85-168 BydgoszczCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland, Jagiellońska 13/15, 85-067 BydgoszczBaltic Clinic Sp. z o.o. Wielkokacka 2, 81-611 Gdynia, PolandIndependent Public Health Care Facility in Szamotuły, Sukiennicza 13, 64-500 Szamotuły Introduction and purpose: Insufficient efficacy and adverse effects of classical therapies for inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn's disease, have prompted the search for new, more targeted treatment methods. Janus kinase (JAK) inhibitors are a new group of oral drugs that modulate the proinflammatory cytokine signaling pathway. The aim of this review is to present the state of knowledge on the efficacy and safety of currently registered JAK inhibitors in the treatment of IBD. Review Methods: A systematic search of the PubMed database was conducted, focusing on publications from the last five years as well as selected key earlier studies. The search strategy included relevant keywords related to Janus kinase (JAK) inhibitors and inflammatory bowel disease (IBD). The most pertinent articles aligned with the study objective were reviewed and included. State of knowledge: JAK inhibitors, such as tofacitinib, upadacitinib, and filgotinib, have shown high efficacy in the treatment of moderate to severe UC and CD, especially in patients with insufficient biological therapy response. Clinical studies confirm their efficacy in inducing and maintaining remission and improving endoscopic findings. The most common adverse events are infections (including herpes zoster), and elevation of creatine kinase and lipids. The safety profile remains acceptable, although it requires monitoring, especially at higher doses, and further investigation. Summary: JAK inhibitors are an effective and promising therapeutic option for IBD, offering a rapid onset of action and good symptom control. Despite the favorable clinical effects, an individual approach to treatment and monitoring for adverse effects are necessary, especially with long-term use. https://apcz.umk.pl/QS/article/view/60398Janus kinase (JAK) inhibitorsCrohn diseaseulcerative colitis |
| spellingShingle | Olimpia Wiciun Karolina Skonieczna Kacper Ordon Magdalena Badziąg Paulina Szulc Laura Kurczoba Martyna Kłossowska Olga Kądziołka Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A Review Quality in Sport Janus kinase (JAK) inhibitors Crohn disease ulcerative colitis |
| title | Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A Review |
| title_full | Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A Review |
| title_fullStr | Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A Review |
| title_full_unstemmed | Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A Review |
| title_short | Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A Review |
| title_sort | janus kinase inhibitors in the treatment of crohn s disease and ulcerative colitis a review |
| topic | Janus kinase (JAK) inhibitors Crohn disease ulcerative colitis |
| url | https://apcz.umk.pl/QS/article/view/60398 |
| work_keys_str_mv | AT olimpiawiciun januskinaseinhibitorsinthetreatmentofcrohnsdiseaseandulcerativecolitisareview AT karolinaskonieczna januskinaseinhibitorsinthetreatmentofcrohnsdiseaseandulcerativecolitisareview AT kacperordon januskinaseinhibitorsinthetreatmentofcrohnsdiseaseandulcerativecolitisareview AT magdalenabadziag januskinaseinhibitorsinthetreatmentofcrohnsdiseaseandulcerativecolitisareview AT paulinaszulc januskinaseinhibitorsinthetreatmentofcrohnsdiseaseandulcerativecolitisareview AT laurakurczoba januskinaseinhibitorsinthetreatmentofcrohnsdiseaseandulcerativecolitisareview AT martynakłossowska januskinaseinhibitorsinthetreatmentofcrohnsdiseaseandulcerativecolitisareview AT olgakadziołka januskinaseinhibitorsinthetreatmentofcrohnsdiseaseandulcerativecolitisareview |